Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Cogent Biosciences (COGT) Invested Capital (2017 - 2026)

Cogent Biosciences' Invested Capital history spans 10 years, with the latest figure at $607.7 million for Q1 2026.

  • Quarterly Invested Capital rose 177.49% to $607.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $607.7 million through Mar 2026, up 177.49% year-over-year, with the annual reading at $636.4 million for FY2025, 148.31% up from the prior year.
  • Invested Capital came in at $607.7 million for Q1 2026, down from $636.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $636.4 million in Q4 2025 to a low of $155.0 million in Q2 2025.
  • The 5-year median for Invested Capital is $302.5 million (2025), against an average of $321.9 million.
  • Year-over-year, Invested Capital tumbled 58.46% in 2025 and then surged 177.49% in 2026.
  • Cogent Biosciences' Invested Capital stood at $255.7 million in 2022, then increased by 0.81% to $257.8 million in 2023, then fell by 0.59% to $256.3 million in 2024, then surged by 148.31% to $636.4 million in 2025, then fell by 4.51% to $607.7 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Invested Capital are $607.7 million (Q1 2026), $636.4 million (Q4 2025), and $302.5 million (Q3 2025).